Comparison of HbA1c in Chinese patients with type 1 or type 2 diabetes randomized to twice daily insulin lispro low mix 25 or twice daily human insulin mix 30/70 / 中华医学杂志(英文版)
Chinese Medical Journal
;
(24): 2540-2546, 2009.
Artigo
em Inglês
| WPRIM
| ID: wpr-307866
ABSTRACT
<p><b>BACKGROUND</b>Glycemic control prevents onset and progression of diabetes-related long-term complications. The objective of this study was to demonstrate that twice daily insulin lispro low mix 25 is noninferior to twice daily human insulin mix 30/70 in achieving glycemic control as measured by hemoglobin A1c (HbA1c), from baseline to endpoint, in patients with type 1 or 2 diabetes.</p><p><b>METHODS</b>In this phase IV, crossover, open-label, multicenter study, 117 Chinese patients with diabetes were randomly assigned to one of two treatment sequence groups. One group received 12-week treatment with twice daily human insulin mix 30/70 followed by 12-week treatment with twice daily insulin lispro low mix 25, while the other group received the reverse treatment sequence. HbA1c, baseline-to-endpoint change in HbA1c, proportion of patients achieving target HbA1c <or= 7% and <or= 6.5%, fasting blood glucose, and daily insulin doses were measured for each period. Safety and tolerability were also assessed.</p><p><b>RESULTS</b>A statistically significant reduction (P <or= 0.0001) of HbA1c was achieved after each treatment (human insulin mix 30/70 mean HbA1c = 7.91% (95%CI 7.67%, 8.15%); insulin lispro low mix 25 mean HbA1c = 7.96% (95%CI 7.72%, 8.20%)). The 95%CI (-0.20, 0.10) of the difference between the two treatments satisfied the prespecified noninferiority margin of 0.3% (lower limit of 95% CI > -0.3%). No statistically significant differences between treatments were observed for any of the secondary efficacy measures. The incidence of treatment-emergent adverse events and hypoglycemia between the two treatments and treatment sequence groups was similar. Three serious adverse events were reported (human insulin mix 30/70 group 2 patients (1.7%, hypoglycemic coma and cardiac failure); insulin lispro low mix 25 group 1 patient (0.9%, stroke)). All serious adverse events were resolved and no patients died during the study.</p><p><b>CONCLUSION</b>The results support noninferiority of twice daily insulin lispro low mix 25 versus twice daily human insulin mix 30/70 in HbA1c control in Chinese patients with type 1 or 2 diabetes.</p>
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Hemoglobinas Glicadas
/
Esquema de Medicação
/
Povo Asiático
/
Diabetes Mellitus Tipo 1
/
Diabetes Mellitus Tipo 2
/
Tratamento Farmacológico
/
Insulina Lispro
/
Hipoglicemiantes
/
Insulina
/
Metabolismo
Tipo de estudo:
Ensaio Clínico Controlado
Limite:
Adolescente
/
Adulto
/
Idoso
/
Feminino
/
Humanos
/
Masculino
Idioma:
Inglês
Revista:
Chinese Medical Journal
Ano de publicação:
2009
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS